Biologia, Bratislava 54/Suppl. 6: 145-150, 1999.

ISSN 0006-3088 (Biologia). ISSN 1335-6399 (Biologia. Section Cellular and Molecular Biology).

 

Full paper

A first experience with in vitro testing of the sensitivity of brain tumor cells sensitivity to chemotherapeutic drugs.

 

Andrej Mirossay1, Jan Mojzis1, Igor Sulla2, Jozef Vyrostko2, Ladislav Sokol3 & Ladislav Mirossay1*

1 Department of Pharmacology, Medical Faculty, P. J. Safarik University, Tr. SNP 1, SK-04066 Kosice, SLovakia; tel.: ++421 95 6423534, fax: ++421 95 6428524, e-mail: mirossay@central.medic.upjs.sk

2 Department of Neurosurgery, Medical Faculty, P. J. Safarik University and University Hospital, Tr. SNP 1, SK-04066 Kosice, Slovakia

3 Department of Pathology, University Hospital, Tr. SNP 1, SK- 04066 Kosice, Slovakia

* corresponding author

Received: December 28, 1998 / Accepted: October 5, 1999

 

Abstract

Brain cancer is unregulated cell proliferation with the additional property of invasiveness. The recurrence of human gliomas several months after surgical treatment (wheter or not accompanied by radio or chemotherapy) suggests that intrinsic resistance to all kinds of therapies underlies the failure of therapy. The aim of this paper was to determine in vitro chemosensitivity of brain tumor cells isolated from patients suffering from disease. Brain tumor cells were evaluated in 12 patients with diagnosis of glioblastoma (WHO grade IV). A histoculture drug response assay was used for the determinantion of chemoresitance. The results revealed a high variability of the tumor samples in response to three selected chemotherapeutic agents: cisplatin, dacarbazine and taxol. The variations in LC50 in these drugs were in the range from 0.71 to 98.3 mg.mL-1 for cisplatin, from 39.9 to 431.4 mg.mL-1 for dacarbazine and from 5.1 to 44.5 mg.mL-1 for taxol. In vitro variabilty is comparable with the in vivo clinical response variabilty found in relavent literature. According to our results the most effective agent in in vitro testing seemed to be dacarbazine which is in good agreement with clinical experience in its uses and this finding is supported by clinical experience of the use of this drug. Although more experiments and a direct comparison with the clinical outcome in every single patient is needed to support our preliminary results a histoculture drug response assay can play an important clinical role in the optimization of individualized cancer chemotherapy.

 

Key words: glioma, in vitro chemosensitivity, MTT, taxol, cisplatin, dacarbazine.